Boston Scientific to buy Target

Article

Acquisition-minded Boston Scientific plans to add another companyto its portfolio. The Natick, MA, catheter developer last monthannounced an agreement to acquire Target Therapeutics, a Fremont,CA, company that develops catheters and other devices used

Acquisition-minded Boston Scientific plans to add another companyto its portfolio. The Natick, MA, catheter developer last monthannounced an agreement to acquire Target Therapeutics, a Fremont,CA, company that develops catheters and other devices used inminimally invasive procedures to treat neurovascular diseases.Target also has a strong position in interventional neuroradiology.

Boston Scientific plans to trade 1.07 shares of its stock foreach Target share in a stock swap valued at $1.1 billion. Targetlast week posted revenues for its third quarter of fiscal 1997(end-December) of $23.9 million, compared with $19 million inthe same period of fiscal 1996. The company had third-quarternet income of $3.8 million, compared with $3.6 million in thesame period a year ago. The acquisition is expected to close inthe second quarter.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.